Table 1.

Pattern of presentation of idiopathic polypoidal choroidal vasculopathy in Ibadan

Patient	Age (years)	Gender	Presentation	Presenting VA (R and L)	Retina signs	Treatment	Outcome VA (R and L)
1	68	F	Sudden visual loss	R, 6/36; L, 6/60	Peripheral exudates, bilateral	–	R, 6/36; L, 6/60
2	47	F	Sudden visual loss	R, LP; L, 6/24	VH, bilateral	R vitrectomy	R, CF; L, HM
3	47	F	Sudden visual loss	R, HM; L, LP	Unilateral VH	R, vitrectomy	R, 6/24; L, LP
4	55	F	Sudden visual loss	R, CF; L, 6/9	VH, RPE detached bilaterally	R, vitrectomy L, Avastin	R, 6/12; L, 6/36
5	67	F	Sudden visual loss	R, 6/36; L, HM	Bilateral VH, RPE detachment, scarred macula	L, Avastin	R, HM; L, CF
6	59	M	Sudden visual loss	R, HM; L, NLP	Unilateral VH	Vitrectomy	R, CF; L, NLP
7	63	M	Sudden visual loss	R, HM; L, NLP	Unilateral VH Scar, orange lesion	Vitrectomy PDT	R, CF; L, LP
8	56	F	Recurrent sudden visual loss	R, HM; L, 6/60	Bilateral RPE detachment, Subretinal hemorrhage. R, macular scar, orange lesion	Bevacizumab PDT	R, CF; L, 6/60
9	54	F	Sudden visual loss	R, 6/9; L, 6/5	Unilateral extrafoveal orange lesions, hemorrhage, RPE detachment	Bevacizumab, focal laser	R, 6/9; L, 6/5
10	63	F	Sudden bilateral visual loss	R, HM; L, CF	Orange lesions, RPE detachment, macular exudates	Bevacizumab	R, CF; L, CF

Abbreviations: R, right; L, left; HM, hand motion; CF, count fingers; LP, light perception; NLP, nil light perception; PDT, photodynamic therapy; RPE, retinal pigment epithelium; VH, vitreous hemorrhage; VA, visual acuity.